We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,775

Trump Administration Lifts Ban On Biotechnology Crops In Wildlife Refuges
  • Bergeson & Campbell PC
  • USA
  • August 17 2018

On August 2, 2018, the Trump Administration’s Principal Deputy Director of the U.S. Fish and Wildlife Service, Gregory J. Sheehan, reversed an Obama

AbbVie Files Suit Against Sandoz Alleging Infringement of Two Humira-Related Patents
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 14 2018

On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz International GMBH

Life sciences: product regulation and liability in Turkey
  • NSN Law Firm
  • Turkey, Global
  • July 11 2018

A structured guide to product regulation and liability laws in Turkey

Innovation key to driving success in healthcare
  • Boult Wade Tennant
  • USA, United Kingdom
  • July 3 2018

As the NHS turns 70, it is notable that the focus for the future is on innovation for the improvement of patient care. Technologies spanning genetic

PTAB Denies Another IPR Petition Relating to Adalimumab
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 14 2018

The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of AbbVie’s patent, U.S

Capital Markets Alert - Public Market Advocacy Groups Release Guidance
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • May 10 2018

On April 27, 2018, the Securities Industry and Financial Markets Association (SIFMA), the U.S. Chamber of Commerce and Nasdaq, along with certain

The Budget 2018-2019: our three key areas for intellectual property
  • King & Wood Mallesons
  • Australia
  • May 9 2018

Biotechnology companies and generic pharmaceuticals are the winners and celebrities are the Biggest Losers in some intellectual property-related

Hong Kong Launches New Rules on Biotech Listings
  • Slaughter and May
  • Hong Kong
  • May 8 2018

The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies and

New chapter on listing of pre-revenue biotech companies in HK: At a glance
  • Deacons
  • Hong Kong
  • May 4 2018

On 24 April 2018, The Stock Exchange of Hong Kong Limited (the “Exchange”) published the consultation conclusions and announced the new rules to: (a

New Hong Kong Dual-Class and Biotech Companies Listing Regime
  • Latham & Watkins LLP
  • Hong Kong
  • May 3 2018

Hong Kong Stock Exchange introduces new listing regime for pre-revenue biotech companies and innovative companies with weighted voting rights